Jeremy Jones

Dr. Jeremy Jones

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2022 in The Oncologist
Verified
Journal Article
Open access
PDF file
MSMohamad Sonbol
Mohamad Sonbol
RSRabbia Siddiqi
Rabbia Siddiqi
Pedro Luiz Serrano Uson JuniorPedro Luiz Serrano Uson Junior
Pedro Luiz Serrano Uson Junior
SPSurabhi Pathak
Surabhi Pathak
BFBelal Firwana
Belal Firwana
TBTanios Bekaii-Saab
Tanios Bekaii-Saab
Background: Despite multiple randomized trials, the role of perioperative chemotherapy in colorectal cancer liver metastasis (CRLM) is still under debate. In this systematic review and network meta-analysis (NMA), we aim to evaluate the efficacy of perioperative systemic therapies for patients with CRLM. Methods: We searched various databases for abstracts and full-text articles published from database inception through May 2021.We included randomized controlled trials (RCTs) comparing the addition of perioperative (post, pre, or both) systemic therapies to surgery alone in patients with CRLM. The outcomes were compared according to the chemotherapy regimen using a random effects model. Outcomes of interest included disease-free survival (DFS) and overall survival (OS). Results: Seven RCTs with a total of 1504 patients with CRLM were included. Six studies included post-operative treatment and one evaluated perioperative (pre- and postoperative) therapy. Fluoropyrimidine-based chemotherapy was the most used systemic therapy. NMA showed benefit of adding perioperative therapy to surgery in terms of DFS (HR 0.73, 95% CI 0.63 to 0.84). However, these findings did not translate into a statistically significant OS benefit (HR 0.88, 95% CI 0.74 to 1.05). NMA did not show any advantage of one regimen over another including oxaliplatin or irinotecan. Conclusions: This systematic review and NMA of 7 RCTs found that the addition of perioperative systemic treatment for resectable CRLM could improve disease-free survival but not overall survival. Based on the findings, addition of perioperative treatment in resectable CRLM should be individualized weighing the risks and benefits.

11 April 2023 in Cureus
Verified
Journal Article
Open access
PDF file
JJJeremy Jones
Jeremy Jones
MGMichael A Golafshar
Michael A Golafshar
TCTucker W. Coston
Tucker W. Coston
RRRohit Rao
Rohit Rao
EWEwa Wysokinska
Ewa Wysokinska
NSN. Jewel Samadder
N. Jewel Samadder
Background Detection of pathogenic germline variants (PGVs) has implications for cancer screening, prognosis, treatment selection, clinical trial enrollment, and family testing. Published guidelines provide indications for PGV testing, determined by clinical and demographic factors, but their applicability in an ethnically and racially diverse community hospital population is unknown. This study describes the diagnostic and incremental yield of universal multi-gene panel testing in a diverse population in a community cancer practice. Methods We completed a prospective study of proactive germline genetic sequencing among patients with solid tumor malignancies at a community-based oncology practice in downtown Jacksonville, FL, between June 2020 and September 2021. The patients were unselected for cancer type, stage, family history, race/ethnicity, and age. PGVs identified using an 84-gene next-generation sequencing (NGS) tumor genomic testing platform were stratified by penetrance. National Comprehensive Cancer Networks (NCCN) guidelines determined incremental PGV rates. Results Two hundred twenty-three patients were enrolled, with a median age of 63 years, 78.5% female. 32.7% were Black/African American, and 5.4% were Hispanic. 39.9% of patients were commercially insured, Medicare/Medicaid insured 52.5%, and 2.7% were uninsured. The most common cancers in this cohort were breast (61.9%), lung (10.3%), and colorectal (7.2%). Twenty-three patients (10.3%) carried one or more PGVs, and 50.2% carried a variant of uncertain significance (VUS). Though there was no significant difference in the rate of PGVs based on race/ethnicity, African Americans were numerically more likely to have a VUS reported than whites (P=0.059). Eighteen (8.1%) patients had incremental clinically actionable findings that practice guidelines would not have detected, which was higher in non-whites. Conclusions In this racially/ethnically and socioeconomically diverse cohort, universal multi-gene panel testing (MGPT) increased diagnostic yield over targeted guideline-informed testing. Rates of VUS and incremental PGV were higher in non-white populations.

21 September 2012 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Open access
PDF file
KCKeith Cooper
Keith Cooper
JSJonathan Shepherd
Jonathan Shepherd
JPJo Picot
Jo Picot
JJJeremy Jones
Jeremy Jones
JKJosephine Kavanagh
Josephine Kavanagh
APAlison Price
Alison Price
Objectives: Reducing sexually transmitted infections (STI) and teenage pregnancy through effective health education is a high priority for health policy. Behavioral interventions which teach skills to practice safer sex may reduce the incidence of STIs. We evaluated the cost-effectiveness of school-based behavioral interventions in young people.Methods: We developed an economic model to estimate the total number of STI cases averted, consequent gain in health related quality of life (HRQoL) and savings in medical costs, based on changes in sexual behavior. The parameters for the model were derived from a systematic literature search on the intervention effectiveness, epidemiology of STIs, sexual behavior and lifestyles, HRQoL and health service costs.Results: The costs of providing teacher-led and peer-led behavioral interventions were €5.16 and €18 per pupil, respectively. For a cohort of 1000 boys and 1000 girls aged 15 years, the model estimated that the behavioral interventions would avert two STI cases and save 0.35 Quality Adjusted Life Years (QALYs). Compared to standard education, the incremental cost-effectiveness of the teacher-led and peer-led interventions was €24,268 and €96,938 per QALY gained, respectively.Conclusions: School-based behavioral interventions which provide information and teach young people sexual health skills can bring about improvements in knowledge and increased self-efficacy, though these may be limited in terms of impact on sexual behavior. There was uncertainty around the results due to the limited effect of the intervention on behavioral outcomes and paucity of data for other input parameters.

17 September 2025 in Liver Transplantation
Verified
Journal Article
Closed access
JJJeremy Jones
Jeremy Jones
CTC. Burcin Taner
C. Burcin Taner
COConnor O’dOnnell
Connor O’dOnnell
RFRebecca Fischer
Rebecca Fischer
SISamantha Inabinett
Samantha Inabinett
KCKristopher P. Croome
Kristopher P. Croome
Despite European colorectal liver metastases (CRLM) transplant trials having been performed entirely using deceased donor liver transplant (DDLT), there has been speculation about whether similar results can be achieved in the United States, given the lack of MELD score prioritization. A formal transplant protocol for unresectable CRLM was implemented in our center at the start of 2022 with the plan to utilize DDLT. Between 2022 and 2025, 86 patients with CRLM were referred to our program, and 19 patients underwent a formal transplant evaluation. Median time from listing until transplant was 31 days (range 3–115 d). Median allocation MELD was 8 (range 6–15). The donor livers were from DCDs, older donors, or National Share livers, which had been declined by all other centers. All but 2 of the cases underwent advanced perfusion. There were no cases of primary nonfunction, postreperfusion syndrome, acute kidney injury, hepatic artery thrombosis, or ischemic cholangiopathy. The length of stay for the median posttransplant was 5 days. Graft and patient survival were 100% at the time of maximal follow-up. Recurrence developed in 3 recipients (25.0%), 1 of whom was treated and has no evidence of disease. These findings support the viability of DDLT for CRLM using advanced perfusion, contingent on strict protocol adherence. Center-specific waitlist dynamics must inform the choice between DDLT and living donor liver transplant (LDLT).

1 March 2026 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
GCGuilherme Sacchi de Camargo Correia
Guilherme Sacchi de Camargo Correia
AHAntonious Ziad Hazim
Antonious Ziad Hazim
BZBinbin Zheng-Lin
Binbin Zheng-Lin
NGNicole Gannon
Nicole Gannon
ABAshton W. R. Boyle
Ashton W. R. Boyle
RMRami Manochakian
Rami Manochakian
PURPOSE: Artificial intelligence (AI) has been rapidly evolving in medicine. While there are existing data about the perceptions and concerns of health care workers regarding AI, those of the hematology and oncology (HemOnc) workforce remain unknown. We assessed opinions of physicians (faculty and fellows), advanced practice providers (APPs), and nurses in HemOnc on integrating AI in medical education (MedEd) and clinical practice (CP). METHODS: Group-specific electronic surveys were developed. The HemOnc workforce from the three Mayo Clinic sites was invited to participate. Participation was anonymous, with data collection between November 7, 2024, and January 20, 2025. Results were reported as proportions, with 95% binomial CI when appropriate. RESULTS: A total of 344 participants responded, 118 physicians (77 faculty, 41 fellows), 49 APPs, and 177 nurses. Most had used AI although less than half felt very or moderately knowledgeable about it. A total of 95% of fellows, 97% of faculty physicians, 96% of APP, and 92% of nurses believe that AI will be integrated in MedEd. A total of 94% of physicians and 88% of nonphysicians believe that this integration would be beneficial. In CP, 98% of fellows, 96% of faculty physicians, 100% of APPs, and 92% of nurses believe in AI's integration. However, 51% of physicians and 68% of nonphysicians had some concerns, including technology time, medical costs, and burnout. Nonetheless, 85% of fellows, 94% of faculty physicians, 98% of APPs, and 86% of nurses would embrace AI. CONCLUSION: The majority of this single health system HemOnc's workforce endorsed AI integration into MedEd and CP but highlighted relevant concerns. Proper education, effective partnership among all stakeholders, and well-organized integration are essential for optimizing AI's incorporation into HemOnc's MedEd and CP and ensuring that it fully supports the mission of providing high-quality patient care.

14 September 2021 in ONCOLOGY
Verified
Journal Article
Open access
KCKristen Ciombor
Kristen Ciombor
JJJeremy Jones
Jeremy Jones
JSJohn H Strickler
John H Strickler
TBTanios Bekaii-Saab
Tanios Bekaii-Saab
CWChristina Wu
Christina Wu
Patients with colorectal cancer could benefit from the COLMATE platform as it allows for opportunities in clinical trial enrollment.